Every material Form 8-K CervoMed Inc. has filed with the SEC since October 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On October 29, 2026, CervoMed announced two peer-reviewed publications on neflamapimod for dementia with Lewy bodies (DLB). The placebo-controlled RewinD-LB Phase 2b trial, published in Alzheimer's Research & Therapy, did not confirm the Phase 2a results on its primary outcome in the full patient population, though the company cites subgroup and biomarker findings it says support further development.
RewinD-LB trial (159 patients) did not confirm the Phase 2a AscenD-LB primary outcome, change in CDR-SB, in the full intention-to-treat population.
In patients without Alzheimer's co-pathology (pTau181 <23 pg/mL), the placebo-adjusted CDR-SB difference was −0.51 points (95% CI: −1.16 to 0.13).
Discontinuation due to adverse events was 2.5% with neflamapimod and 1.3% with placebo.
The company is focused on identifying a strategic partner to advance neflamapimod into a Phase 3 trial in DLB.
CervoMed Inc. filed an 8-K furnishing an investor presentation covering its business, clinical studies, development plans and financial position, posted on its website. The filing contains no financial results, guidance or new figures, so shareholders have no new numbers to assess from the filing itself.
Presentation posted on cervomed.com under Investors – Events and Presentations.
Company may use the presentation at investor conferences and meetings, in whole or in part.
Filing is furnished under Item 7.01, not deemed filed under Section 18 of the Exchange Act.
Filing is signed by William Elder, Chief Financial Officer & General Counsel, dated October 14, 2026.
CervoMed reported initial 12-week biomarker data from its open-label Phase 2a trial of neflamapimod in nonfluent variant primary progressive aphasia, presented October 12, 2026 at the ISFTD annual meeting. The average plasma neurofilament light chain level declined, but the trial has 25 participants and no placebo or control group during the open-label period, so the results are early. The filing contains no revenue or financial results, and the company expects 24-week biomarker data in November 2026 and topline clinical data in the first quarter of 2027.
Mean plasma NfL change was about -3.1 pg/mL over the first 12 weeks across 25 participants, with most of the decline between weeks six and 12.
In an exploratory subgroup with baseline NfL at or above the median (n=13), mean NfL change was about -5.7 pg/mL over 12 weeks; GFAP levels were stable.
One patient met protocol criteria for discontinuation due to elevated liver enzymes; the company reported no new safety signals.
24-week biomarker data will be presented at CTAD in November 2026; clinical data are expected in the first quarter of 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CervoMed Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →